Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

Apr

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

NCCN Names New Chief Scientific Officer

Global Survival Index for Childhood Cancer CONCORD-4

Ablative Radiotherapy May Improve Outcomes for Patients With Large Intrahepatic Cholangiocarcinoma

Patients With Lung Cancer May Safely Receive Adequate SBRT Dosage in One Treatment

Can Saying I Do Reduce Cancer Risk